Objective: This study investigated the release, absorption and elimination profile of preoperatively administered sustained-release morphine (Kapanol™) and its metabolites in patients undergoing surgery and general anaesthesia.
Methods: Sustained-release morphine 50mg (37.6mg of morphine base) was administered 1 to 2 hours before induction of anaesthesia in 10 patients undergoing elective surgery.
Results: Mean plasma concentration-time curves showed a time to peak concentration (tmax) of 8.4 ± 6.5 hours for morphine and 10.4 ± 10.3 hours for both morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G). The absorption half-life of morphine was 5.7 ± 6.9 hours. The ratio of the areas under the concentration-time curves for morphine, M6G and M3G was 1: 3.5: 28. The elimination half-lives of morphine and its metabolites were not significantly different at 15.0 ± 8.95 hours.
Conclusions: After preoperative oral administration, sustained-release morphine 50mg was absorbed perioperatively in all 10 patients studied. The mean plasma concentration-time curve for morphine resembled that in healthy (nonsurgical) adult males receiving a single dose, and the concentrations attained would be expected to provide postoperative analgesia.
Morphine Adis International Limited Mean Residence Time Clin Drug Invest Postoperative Pain Management
This is a preview of subscription content, log in to check access
Breivik H. Postoperative pain management: why is it difficult to show that it improves outcome? Eur J Anaesthesiol 1998; 15:748–51PubMedCrossRefGoogle Scholar
Breivik H, Högström H, Neimi G. Safe and effective postoperative pain relief: introduction and continuous quality improvement of comprehensive post-operative pain management programmes. Ballière’s Clin Anaesth 1995; 9: 423–60CrossRefGoogle Scholar
Roseag OP, Lui AC, Vicutti NJ, et al. Peri-operative multimodal pain therapy for caesarean section: analgesia and fitness for discharge. Can J Anaesth 1997; 44: 803–9CrossRefGoogle Scholar
Broomhead A, Kerr R, Tester W, et al. Comparison of a one-a-day sustained release morphine formulation with standard oral morphine treatment for cancer pain. J Pain Symptom Manage 1997; 14: 63–73PubMedCrossRefGoogle Scholar
Zandsberg S, Rosenblum M. Nonconventional drug administration in anesthesia. Anesth Clin North Am 1994; 12: 17–38Google Scholar
Berg-Dahl J. Neuronal plasticity and pre-emptive analgesia: implications for the management of postoperative pain. Dan Med Bull 1994; 41: 434–42Google Scholar
Bamber MJ, Tweedie IE, Breeze C, et al. Premedication with controlled release diclofenac sodium reduces post-operative pain after minor gynaecological surgery. Eur J Anaesthesiol 1997; 14: 421–7PubMedCrossRefGoogle Scholar
Woolf CJ, Chong MS. Pre-emptive analgesia; treating postoperative pain by preventing the establishment of central sensitisation. Anesth Analg 1993; 77: 329–31Google Scholar
Gourlay GK, Plummer JL, Cherry DA, et al. A comparison of Kapanol (a new sustained release morphine formulation), MST Continus, and morphine solution in cancer patients: pharmacokinetic aspects of morphine and morphine metabolites. Proceedings of the 7th World Congress on Pain, 1994; 2:631–43Google Scholar
Clinical Investigator Brochure Kapanol™ Capsules. Glaxo Australia Pty Ltd. 3rd ed. March 1993Google Scholar
Flöter T, Koch EMW. Comparison of two oral morphine formulations for chronic severe pain of malignant and non-malignant origin: Kapanol vs MST. Clin Drug Invest 1997; 14: 183–91CrossRefGoogle Scholar
Koopman-Kimenai PM, Vree TB, Cress-Tijhuis MW, et al. High performance liquid chromatography and preliminary pharmacokinetics of nicomorphine and its metabolites 3-nicotinoyl- and 6-nicotinoylmorphine and morphine. J Chromatogr 1987; 416: 382–7PubMedCrossRefGoogle Scholar
Proost JH, Meijer DKW MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comp Biol Med 1992; 22: 155–62CrossRefGoogle Scholar
Lötsch J, Stockmann A, Kobal G, et al. Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther 1996; 60: 316–25PubMedCrossRefGoogle Scholar
Maccarone C, West RJ, Broomhead AF, et al. Single dose pharmacokinetics of Kapanol, a new oral sustained-release morphine formulation. Drug Invest 1994; 7: 262–74Google Scholar
Houston JB. Kinetics of disposition of xenobiotics and their metabolites. Drug Metabol Drug Interact 1988; 6: 47–83PubMedGoogle Scholar
Bodd E, Jacobsen D, Lund E, et al. Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Hum Exp Toxicol 1990; 9: 317–21PubMedCrossRefGoogle Scholar
Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites of the pharmacological effects of morphine. Drug Metab Rev 1996; 28: 345–72PubMedCrossRefGoogle Scholar
Hanna MH, Peat SJ, Knibb AA, et al. Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br J Anaesth 1991; 66: 103–7PubMedCrossRefGoogle Scholar
Portenoy RK, Thaler HT, Inturrisi CE, et al. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 1992; 51: 422–31PubMedCrossRefGoogle Scholar
Francés B, Gout R, Campistron G, et al. Morphine-6-glucuronide is more mu-selective and potent in analgesic tests than morphine. The International Narcotics Research Conference (INRC) 1989. New York: AR Liss Inc, 1990: 477–80Google Scholar
Thompson PI, Hucks D, McLoughlin L, et al. Comparative opiate receptor affinities of morphine and its active metabolite morphine-6-glucuronide [abstract]. Br J Cancer 1990; 62:484CrossRefGoogle Scholar
Hagen NA, Foley KM, Cerbone DJ, et al. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 1991; 6: 125–8PubMedCrossRefGoogle Scholar